Status:
UNKNOWN
Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone
Lead Sponsor:
Thomas Jefferson University
Collaborating Sponsors:
Bayer
Novartis Pharmaceuticals
Conditions:
Differentiated Thyroid Cancer
Eligibility:
All Genders
18-89 years
Phase:
PHASE2
Brief Summary
The goal of this study is to determine the effect of combining everolimus and sorafenib in patients with metastatic differentiated thyroid cancer who progressed on sorafenib alone.
Detailed Description
The purpose of this research study is to: 1. Find out if sorafenib and everolimus prevent the growth of tumors that have grown when treated with sorafenib alone 2. Find out how long one might benefit...
Eligibility Criteria
Inclusion
- Diagnosis of thyroid cancer, that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective.
- All patients will have been required to have had sorafenib for entry and have had documented progression while on previous treatment with sorafenib.
- Measurable disease defined as at least one malignant lesion that can be accurately measured on computerized tomography (CT) and/or magnetic resonance imaging (MRI) scan.
- ECOG performance status \< 2.
- Life expectancy greater than 3 months.
- Intellectual, emotional, and physical ability to comply with oral medication.
Exclusion
- Restrictions regarding certain prior treatments will apply.
- Significant medical disease including: uncontrolled congestive heart failure; active symptoms of coronary artery disease, uncontrolled seizure disorder; active infection; uncontrolled diabetes mellitus; requirement for chronic high dose corticosteroid treatment (Topical or inhaled corticosteroids are allowed); requirement for concurrent immunosuppressive drug(s); active autoimmune disease.
- Organ allografts.
- Known HIV-infection (HIV testing is not required for participation).
- Pregnant or breast feeding. Women of childbearing potential and sexually active males must be advised to take precautions to prevent pregnancy during treatment
- History of second cancer (except adequately treated basal cell or squamous cell skin cancer, in situ treated cervical cancer, colon cancer or melanoma, or any other cancer for which the patient has been disease-free for three or more years).
- Known hypersensitivity to everolimus or other rapamycins (e.g., sirolimus, temsirolimus) or to its excipients
- Use of any experimental therapy within 4 weeks prior to baseline evaluations done prior to enrollment (with the exception of sorafenib which may be continued until treatment start). Therefore, all experimental treatments other than sorafenib must be discontinued 4 weeks prior to baseline studies or enrollment.
- Patients who did not previously tolerate sorafenib at 200 mg once daily are excluded from the study.
Key Trial Info
Start Date :
November 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2022
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT01263951
Start Date
November 1 2010
End Date
May 1 2022
Last Update
October 26 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104